Subscribe to RSS
DOI: 10.1055/s-2008-1038222
Stellenwert der Transurethralen Resektion der Prostata (TUR-P) bei der Behandlung der symptomatischen benignen Prostataobstruktion (BPO): Eine Analyse zur Effektivität und Komplikationsrate bei 1015 Patienten
Value of Transurethral Resection of the Prostate (TURP) for Treatment of Symptomatic Benign Prostatic Obstruction (BPO): An Analysis of Efficiency and Complications in 1015 CasesPublication History
Publication Date:
16 September 2008 (online)

Zusammenfassung
1015 Patienten mit einer benignen Prostatahyperplasie, die sich in den vergangenen 7 Jahren einer transurethralen Resektion (TUR-P) unterziehen mussten, wurden im Rahmen der Qualitätskontrolle bezüglich Indikationsstellung, Komplikationen und der erzielten Ergebnisse analysiert. Hierbei sollte auch der gegenwärtige Stellenwert der TUR-P mit alternativen Behandlungsformen verglichen werden. Die Transfusionsrate (0,69 %), das TUR-Syndrom (0,78 %) und die Rate an Harnweginfektionen (1,1 %) sind sehr gering. In 4,7 % der Fälle war ein Zweiteingriff, meistens wegen einer Blasentamponade, erforderlich. Die perioperative Mortalität betrug 0,1 %. Bei den Miktionsparametern verbesserte sich der Uroflow relativ um 131 % und der Restharn verminderte sich um 81 %. Niedrige Komplikationsdichte, hohe Effizienz und Zufriedenheit der Patienten sind die entscheidenden Kriterien auch zur Beurteilung alternativer Verfahren. Diese haben zurzeit noch nicht das Potenzial, die TUR-P abzulösen.
Abstract
1015 patients with benign prostatic hyperplasia who underwent transurethral resection (TURP) within the last seven years were analysed concerning indication, complications and results by evaluation of quality. The actual value of TURP should also be compared with that of alternative procedures of treatment. The transfusion rate (0.69 %), TUR syndrome (0.78 %) and the urinary infection rate (1.1 %) are all very low. In 4.7 % a re-operation was necessary, mostly due to significant haematuria. The mortality rate perioperatively was 0.1 %. With regard to the voiding outcome, the uroflow relatively improved in 131 % and post-void residual urine diminished in 81 %. The low rate of complications, high efficiency and satisfaction of the patients are of importance also for the evaluation of alternative procedures. At the present time these modes of treatment do not have the potential to substitute for TURP.
Schlüsselwörter
BPO - TUR-P - Indikation - Komplikationen - Miktionsparameter
Key words
BPO - TURP - indication - complications - voiding outcome
Literatur
- 1
Aagaard J, Jonler M, Fuglsig S. et al .
Total transurethral resection versus minimal transurethral resection of the prostate.
A 10 year follow up study of urinary tract symptoms, uroflowmetry and residual volume.
B J Urol.
1994;
74
333-336
MissingFormLabel
- 2
AUA .
Guideline on management of benign prostatic hyperplasia. Chapter 1: Diagnosis and
treatment recommendations.
J Urol.
2003;
170
530-547
MissingFormLabel
- 3
Berges R, Muschter R, Höfner K.
Alternative, minimalinvasive Therapien beim benignen Prostatasyndrom.
Dtsch Ärztebl.
2007;
104
2209-2218
MissingFormLabel
- 4
Cattolica V, Sidney St, Sadler M C.
The safety of transurethral prostatectomy: a cohort study of mortality in 9416 men.
J Urol.
1997;
158
102-104
MissingFormLabel
- 5
Doll H A, Black A, McPherson K. et al .
Mortality, morbidity and complications following transurethral resection of the prostate
for benign prostatic hypertrophy.
J Urol.
1992;
147
1566-1573
MissingFormLabel
- 6
Hill B, Belville W, Bruskewitz R. et al .
Transurethral needle ablation versus transurethral resection of the prostate for the
treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective,
randomized, multicentre clinical trial.
J Urol.
2004;
171
2336-2340
MissingFormLabel
- 7
Holman C D, Wisniewski Z S, Semmens J B. et al .
Mortality and prostate cancer risk in 19 589 men after surgery for benign prostatic
hyperplasia.
B J U Int.
1999;
84
37-42
MissingFormLabel
- 8
Horninger W, Unterlechner H, Straser H. et al .
Transurethral prostatectomy: mortality and morbidity.
Prostate.
1996;
28
195-200
MissingFormLabel
- 9
Koshiba K, Egawa S, Ohori M. et al .
Does transurethral resection of the prostate pose a risk to life? 22-year outcome.
J Urol.
1995;
153
1506-1509
MissingFormLabel
- 10
Madersbacher S, Lackner J, Brossner C. et al .
Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy:
a nation-wide, long-term analysis of 23 123 cases.
Eur Urol.
2005;
47
499-504
MissingFormLabel
- 11
Madersbacher S, Marberger M.
Is transurethral resection of the prostate still justified?.
B J U Int.
1999;
83
227-237
MissingFormLabel
- 12
Malek R S, Kuntzman R S, Barrett D M.
Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive
prostate: observations on long-term lutcomes.
J Urol.
2005;
174
1344-1348
MissingFormLabel
- 13
Mebust W K, Holtgrewe H L, Cockett A TK. et al .
Transurethral prostatectomy: immediate and postoperative complications. A cooperative
study of 13 participating institutions.
J Urol.
1989;
141
243-247
MissingFormLabel
- 14
Muschter R, Reich O.
Operative und instrumentelle Therapie bei BPH/BPS.
Urologe.
2008;
47
155-165
MissingFormLabel
- 15
Reich O, Seitz M, Gratzke C. et al .
Benignes Prostatasyndrom (BPS).
Der Urologe.
2006;
45
769-780
MissingFormLabel
- 16
Roehrborn C G.
Safety and Efficacy of the Potassium-Titanyl-Phosphate Laser and Photoselective Vaporization
of the Prostate for Benign Prostatic Hyperplasia.
Rev Urol.
2006;
8
16-23
MissingFormLabel
- 17
Shalev M, Richter S, Kessler O. et al .
Long-term incidence of acute myocardial infarction after open and transurethral resection
of the prostate for benign prostatic hyperplasia.
J Urol.
1999;
161
491-493
MissingFormLabel
- 18
de Sio M, Autorino R, Quarto G. et al .
Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a
randomized prospective trial.
Urology.
2006;
67
69-72
MissingFormLabel
- 19
Te A E, Malloy T R, Stein B S. et al .
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy
in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective
multicentre study at 3 years.
B J U.
2006;
97
1229-1233
MissingFormLabel
- 20
Te A E, Malloy R R, Stein B S. et al .
Photoselective vaporization of the prostate for the treatment of benign prostatic
hyperplasia: 12-month results from the first United States multicentre prospective
trial.
J Urol.
2004;
172
1404-1408
MissingFormLabel
- 21
Tugcu V, Tasci A I, Sahin S. et al .
Outcomes of 80 W KTP laser vaporization of the large prostate.
UrolInt.
2007;
79
316-320
MissingFormLabel
- 22
Varkarakis J, Bartsch G, Horninger W.
Long-term morbidity and mortality of transurethral prostatectomy: a 10-year follow-up.
Prostate.
2004;
58
248-251
MissingFormLabel
- 23
Yang Q, Peters T J, Donovan J L. et al .
Transurethral incision compared with transurethral resection of the prostate for bladder
outlet obstruction: a systematic review and metaanalysis of randomised controlled
trials.
J Urol.
2001;
165
1526-1532
MissingFormLabel
- 24
Zwergel U, Wullich B, Lindenmeir U. et al .
Long-term results following transurethral resection of the prostate.
Eur Urol.
1998;
33
476-480
MissingFormLabel
Dr. Harald Zepnick
Urologische Klinik, Krankenhaus Dresden-Friedrichstadt, Städtisches Klinikum, Akademisches
Lehrkrankenhaus der Technischen Universität Dresden
Friedrichstr. 41
01067 Dresden
Phone: 03514801160
Fax: 03514803262
Email: harald.zepnick@ gmx.de